- July 16, 2015New indication – Vectibix® + FOLFIRI in 1st line: What does this mean for patients with wild-type RAS mCRC?The efficacy and safety of Vectibix® + FOLFOX in patients with wild-type RAS mCRC have been established in the phase 3 PRIME trial and in the phase 2 PEAK trial, versus FOLFOX alone and bevacizumab + FOLFOX, respectively.
- January 8, 2015PRIME: Safety and efficacy of Vectibix® + FOLFOX in subgroups of patients with wild-type RAS mCRCWe now know that patients with wild-type RAS (wild-type KRAS and NRAS exons 2–4) mCRC may benefit from Vectibix® + FOLFOX.1,2 However, Vectibix® in combination with FOLFOX chemotherapy has shown a detrimental effect on survival in patients whose tumours carry mutated RAS.
Ask the expert
Learn about key studies of Vectibix® efficacy and safety.
PRIME: wild-type RAS
Click here to find out more about this pivotal trial